Rani Therapeutics (RANI) News Today $2.34 +0.03 (+1.30%) (As of 09/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $11.71September 14, 2024 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Buy" by AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has issued a strong buy ratSeptember 11, 2024 | marketbeat.comRani Therapeutics to Participate in September Investor ConferencesSeptember 3, 2024 | globenewswire.comChemomab Therapeutics: Strong Buy Rating on Robust Financials and Positive Clinical Trial OutcomesAugust 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and CytomX Therapeutics (CTMX)August 22, 2024 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Buy" from AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are currently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and one has given a strongAugust 17, 2024 | marketbeat.comLykos to cut 75% of workforce, founder to exit board after drug setbackAugust 16, 2024 | msn.comHC Wainwright Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $9.00HC Wainwright dropped their target price on Rani Therapeutics from $13.00 to $9.00 and set a "buy" rating on the stock in a report on Friday.August 16, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)August 16, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Reduced by AnalystRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for shares of Rani Therapeutics in a report released on Monday, August 12th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company wiAugust 14, 2024 | marketbeat.comXLerator Network Selects 8 Life Science Startups Across Southeast for NIH-Funded Entrepreneurship Program: I-RED's Second Cohort AnnouncedAugust 14, 2024 | finance.yahoo.comRANI: Second Quarter ResultsAugust 12, 2024 | msn.comInnovative Oral Delivery Platform Drives Buy Rating for Rani Therapeutics HoldingsAugust 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO) and Rani Therapeutics Holdings (RANI)August 7, 2024 | markets.businessinsider.comRani Therapeutics (NASDAQ:RANI) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPSRani Therapeutics (NASDAQ:RANI - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03.August 7, 2024 | marketbeat.comRani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate UpdateAugust 7, 2024 | finance.yahoo.comOppenheimer Initiates Coverage of Rani Therapeutics Holdings (RANI) with Outperform RecommendationAugust 3, 2024 | msn.comRani Therapeutics to Participate in August Investor ConferencesJuly 29, 2024 | globenewswire.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Buy" from AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has been assigned an average rating of "Buy" from the seven brokerages that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating toJuly 23, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)July 22, 2024 | markets.businessinsider.comRani Therapeutics prices securities offering to raise $10 millionJuly 22, 2024 | msn.comRani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct OfferingJuly 22, 2024 | globenewswire.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Buy" from AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has been assigned an average rating of "Buy" from the eight ratings firms that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assignedJune 28, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Rani Therapeutics (NASDAQ:RANI)HC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of Rani Therapeutics in a report on Tuesday.June 25, 2024 | marketbeat.comRani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity TreatmentJune 24, 2024 | globenewswire.comRani Therapeutics (NASDAQ:RANI) Raised to Strong-Buy at Maxim GroupMaxim Group upgraded shares of Rani Therapeutics to a "strong-buy" rating in a research note on Thursday.June 15, 2024 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Coverage Initiated at Rodman & RenshawRodman & Renshaw began coverage on Rani Therapeutics in a research report on Thursday. They set a "buy" rating and a $10.00 price objective on the stock.June 13, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Short Interest Down 29.7% in MayRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 871,200 shares, a drop of 29.7% from the April 30th total of 1,240,000 shares. Based on an average daily volume of 148,400 shares, the short-interest ratio is presently 5.9 days. Currently, 7.5% of the shares of the company are sold short.May 31, 2024 | marketbeat.comRani Therapeutics to Participate in May Investor ConferencesMay 14, 2024 | globenewswire.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Short Interest Down 27.9% in AprilRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 1,240,000 shares, a drop of 27.9% from the April 15th total of 1,720,000 shares. Currently, 10.9% of the shares of the company are short sold. Based on an average daily trading volume, of 144,600 shares, the days-to-cover ratio is currently 8.6 days.May 12, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)May 12, 2024 | markets.businessinsider.comRani Therapeutics (NASDAQ:RANI) PT Raised to $14.00BTIG Research boosted their target price on shares of Rani Therapeutics from $7.00 to $14.00 and gave the stock a "buy" rating in a report on Thursday.May 9, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Buy" from AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among aMay 9, 2024 | marketbeat.comRANI: 1Q:24 ResultsMay 9, 2024 | msn.comRani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024May 9, 2024 | globenewswire.comEdward Nash Maintains Buy Rating on Rani Therapeutics Amid Strong Financials and Promising Clinical TrialsMay 8, 2024 | markets.businessinsider.comRani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic UpdatesMay 7, 2024 | finance.yahoo.comHC Wainwright Raises Rani Therapeutics (NASDAQ:RANI) Price Target to $13.00HC Wainwright boosted their target price on shares of Rani Therapeutics from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday.May 7, 2024 | marketbeat.comRANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024May 6, 2024 | investorplace.comRani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate UpdateMay 6, 2024 | globenewswire.comFavourable Signals For Rani Therapeutics Holdings: Numerous Insiders Acquired StockMay 2, 2024 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)April 23, 2024 | markets.businessinsider.comRANI Rani Therapeutics Holdings, Inc.April 14, 2024 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)April 2, 2024 | markets.businessinsider.comCanaccord Genuity Group Trims Rani Therapeutics (NASDAQ:RANI) Target Price to $9.00Canaccord Genuity Group dropped their price target on Rani Therapeutics from $21.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday.March 27, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Recommendation of "Buy" by AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have received a consensus rating of "Buy" from the five ratings firms that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 moMarch 27, 2024 | marketbeat.comBuy Rating for Rani Therapeutics: Promising Clinical Data and Significant Market PotentialMarch 25, 2024 | markets.businessinsider.comRani Therapeutics (NASDAQ:RANI) PT Lowered to $12.00 at HC WainwrightHC Wainwright reduced their price target on shares of Rani Therapeutics from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Monday.March 25, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | seekingalpha.com Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address The election trade you can't lose (Ad)Politics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends. Download my Dividend Calendar here RANI Media Mentions By Week RANI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RANI News Sentiment▼0.000.49▲Average Medical News Sentiment RANI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RANI Articles This Week▼12▲RANI Articles Average Week Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PYXS News PASG News ALEC News TRDA News QTTB News ALMS News ARCT News ELYM News FULC News VALN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RANI) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
